

# **Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players**

<https://marketpublishers.com/r/L768AE2EBEEDEN.html>

Date: May 2022

Pages: 35

Price: US\$ 2,000.00 (Single User License)

ID: L768AE2EBEEDEN

## **Abstracts**

Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

### **SUMMARY**

Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter

strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

#### **NOTE:**

This is an "on-demand" report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

Certain sections in the report may be removed or altered based on the availability and relevance of data.

#### **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy).

The pipeline guide reviews pipeline therapeutics for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Laminin-Deficient

Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy).

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Report Coverage
- Indication - Overview
- Indication - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Indication - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Indication - Companies Involved in Therapeutics Development
- Company 1
- Company 2
- Company 3
- Company XX
- Indication - Drug Profiles
- Drug 1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 3 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 4 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug XX - Drug Profile

Product Description  
Mechanism of Action  
R&D Progress  
Indication - Dormant Projects  
Indication - Discontinued Products  
Indication - Product Development Milestones  
Featured News & Press Releases  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Indication, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Indication - Pipeline by Company 1, 2022  
Indication - Pipeline by Company 2, 2022  
Indication - Pipeline by Company 3, 2022  
Indication - Pipeline by Company XX, 2022  
Indication - Dormant Projects, 2022  
Indication - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Indication, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Product link: <https://marketpublishers.com/r/L768AE2EBEEDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L768AE2EBEEDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970